12-month Open Label, Randomized, Multicenter Study Evaluating Efficacy, Safety and Tolerability of Oral AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), vs. Mycophenolic Acid Plus Tacrolimus in de Novo Renal Transplant Recipients
Latest Information Update: 06 Oct 2021
At a glance
- Drugs Sotrastaurin (Primary) ; Basiliximab; Mycophenolate sodium; Prednisone; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Novartis
- 05 Oct 2021 The 24 month extension trial has been completed in France (Global end date: 30 May 2008).
- 05 Oct 2021 The 24 month extension trial has been completed in France (Global end date: 30 May 2008).
- 29 Jan 2010 Status changed from completed to discontinued.